Filing Details
- Accession Number:
- 0001493152-22-023376
- Form Type:
- 4
- Zero Holdings:
- No
- Publication Time:
- 2022-08-17 20:17:12
- Reporting Period:
- 2022-08-15
- Accepted Time:
- 2022-08-17 20:17:12
- SEC Url:
- Form 4 Filing
Issuer
Cik | Name | Symbol | Sector (SIC) | IRS No |
---|---|---|---|---|
1642380 | Oncocyte Corp | OCX | In Vitro & In Vivo Diagnostic Substances (2835) | 271041563 |
Insiders
Cik | Name | Reported Address | Insider Title | Director | Officer | Large Shareholder | Other |
---|---|---|---|---|---|---|---|
1806505 | L. Jennifer Carter | C/O Oncocyte Corporation 15 Cushing Irvine CA 92618 | Yes | No | No | No |
Reported Non-Derivative Transactions
Sec. Name | Acquisiton - Disposition | Date | Amount | Price | Remaning Holdings | Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|---|---|---|---|---|---|
Common Stock, No Par Value | Acquisiton | 2022-08-15 | 10,000 | $0.00 | 20,000 | No | 4 | A | Direct | |
Common Stock, No Par Value | Acquisiton | 2022-08-16 | 10,500 | $0.95 | 30,500 | No | 4 | P | Direct |
Equity Swap Involved | Form Type | Code | Nature of Ownership | Explanation |
---|---|---|---|---|
No | 4 | A | Direct | |
No | 4 | P | Direct |
Reported Derivative Transactions
Sec. Name | Sec. Type | Acquisiton - Disposition | Date | Amount | Price | Amount - 2 | Price - 2 |
---|---|---|---|---|---|---|---|
Common Stock | Option to Purchase Common Stock | Acquisiton | 2022-08-15 | 45,000 | $0.00 | 45,000 | $0.97 |
Remaning Holdings | Exercise Date | Expiration Date | Equity Swap Involved | Transaction Form Type | Transaction Code | Nature of Ownership |
---|---|---|---|---|---|---|
45,000 | 2032-08-15 | No | 4 | A | Direct |
Footnotes
- The Restricted Stock Units shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.
- Options shall vest one year from the date of grant, subject to the Reporting Person's continued service as a director of the Issuer from the date of grant until the vesting date or, if earlier, until the next annual meeting of shareholders.